0000000000023872
AUTHOR
K. Vetter
Islet Autoantibodies in Offspring of Mothers with Gestational Diabetes at the Age of 4 to 14 Years
Islet Autoantibodies in Offspring of Mothers with Gestational Diabetes at the Age of 4 to 14 Years
Evidence for Shears Bands in108Cd
High-spin states were populated in ${}^{108}\mathrm{Cd}$ using the ${}^{96}\mathrm{Zr}{(}^{16}\mathrm{O},4n)$ reaction at a beam energy of 72 MeV. Two magnetic dipole bands have been observed, both of which contain weak $E2$ crossover transitions. Lifetimes for the stronger of the two bands were measured via the Doppler shift attenuation method. The configuration assignment for this band has been determined from comparison with tilted axis cranking model calculations to be $\ensuremath{\pi}[{g}_{9/2}^{\ensuremath{-}3}{g}_{7/2}]\ensuremath{\bigotimes}\ensuremath{\nu}[{h}_{11/2}{(g}_{7/2}{d}_{5/2}{)}^{1}]$ and $\ensuremath{\pi}[{g}_{9/2}^{\ensuremath{-}3}{g}_{7/2}]\ensuremath{\bigotimes}\ensu…
Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)
Abstract Background: Although ruxolitinib (RUX) reduces constitutional symptoms and splenomegaly in myelofibrosis (MF) therapy options for anemia are limited. In our prior MPNSG-0109 trial of pomalidomide (POM) in MF with cytopenia, anemia responses were reported in 14% and 29% of subjects receiving POM 0.5 mg/d and 2 mg/d, respectively (Schlenk RF et al., ASH 2013, abstract #2822). We designed a phase-Ib/-II combination study of RUX plus POM to evaluate synergistic effects in subjects with anemia and splenomegaly (MPNSG-0212 trial, NCT01644110; Stegelmann et al., ASH 2015, abstract #826). Study Design: Primary endpoints are response rate after 12 treatment cycles (28 days each) according t…